Expired NOT-DC-19-007: Notice of Special Interest (NOSI) of NIDCD and NEI in Supporting Research on Usher Syndrome

Notice of Special Interest (NOSI) of NIDCD and NEI in Supporting Research on Usher Syndrome

Notice Number: NOT-DC-19-007

Key Dates
Release Date: September 4, 2019
First Available Due Date: October 5, 2019
Expiration Date: September 8, 2022

Related Announcements
NOT-DC-18-007 Notice of NIDCD and NEI Interest in Supporting Research on Usher Syndrome

Issued by
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Eye Institute (NEI)

Purpose

NOT-DC-18-007 is being reissued to provide new guidance on how to identify applications submitted in response to this NOSI so they can be identified.

Background:

Usher syndrome is the most common condition that affects both hearing and vision; sometimes it also affects balance. The major symptoms of Usher syndrome are deafness or hearing loss and an eye disease known as retinitis pigmentosa. The purpose of this notice is to express the joint interest of the National Institute on Deafness and Other Communication Disorders(NIDCD) and the National Eye Institute(NEI) in receiving applications for clinical, translational and basic research designed to ultimately prevent, restore or treat hearing loss, deafness, balance and vision loss caused by Usher syndrome.

Research Objectives:

Areas of Usher syndrome research encouraged through this Notice include, but are not limited to:

Translation of basic laboratory research findings into best clinical practices that preserve or restore the vision, hearing and balance in individuals with Usher syndrome
Studies related to disease pathogenesis and genetic factors that underlie structure, function, and the biology of Usher syndrome and their functional consequences for the purpose of developing clinical interventions
Development of model systems more reflective of the disease in humans
Studies that move beyond in vitro and animal models into humans
Strategies to accelerate the identification of molecular targets for therapeutic drug development
Collaborative studies between hearing and vision scientists that will identify common factors in the etiology of Usher syndrome that may lead to multi-purpose therapy development
Development of devices to improve quality of life
Studies that explore the role of non-Mendelian genetics, including epigenetic modifications, microRNA gene regulation, mitochondrial genetics and genetic modifier effects in Usher Syndrome

Application and Submission Information:

This notice applies to due dates on or after October 5, 2019 and subsequent due dates through September 8, 2022.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice:

Activity Code	FOA	First Available Due Date
U01	PAR-18-340 NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 Clinical Trials Required)	October 21, 2019
R01	PA-18-334 NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required)	October 5, 2019
R01	PA-19-056 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	October 5, 2019
R01	PA-18-351 NEI Human Subjects Mechanistic and Minimal Risk Studies (R01 Clinical Trial Optional)	October 5, 2019
R21	PA-19-092 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)	October 16, 2019
R21	PA-19-053 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)	October 16, 2019
R21	PA-18-500 NEI Human Subjects Mechanistic and Minimal Risk Studies (R21 Clinical Trial Optional)	October 16, 2019
R21	PAR-18-487 NIDCD Early Career Research(ECR) Award (R21 - Clinical Trials Optional)	October 28, 2019
R24	PAR-18-707 NEI Translational Research Program (TRP) on Therapy for Visual Disorders (R24 Clinical Trial Optional)	January 25, 2020
R01	PAR-18-533 NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trials Optional)	October 18, 2019
P50	PAR-19-137 NIDCD Clinical Research Center Grant (P50 - Clinical Trials Optional)	October 4, 2019
UG1	PAR-18-521 NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)	January 25, 2020
UG1	PAR-18-522 UG1 Clinical Research Cooperative Agreements - Single Project	January 25, 2020
UG1	PAR-18-523 UG1 Clinical Research Cooperative Agreements Single Project	January 25, 2020

Other Parent FOAs for Research (R), Career Development (K), and Fellowship (F) awards in which NIDCD and NEI participate can also be used (see "Parent Announcements (for Unsolicited or Investigator Initiated Applications)": https://grants.nih.gov/grants/guide/parent_announcements.htm).

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

For funding consideration, applicants must include "NOT-DC-19-007" (without quotation marks) in the Agency Routing Identifier field (box 4b) of the SF424 R&R form. Applications without this information in box 4b will not be considered for this initiative.

Inquiries

Please direct all inquiries to:

Bracie Watson, Jr., Ph.D.
National Institute on Deafness and Other Communication Disorders
Telephone: 301-402-3458
Email: [email protected]

Grace Shen, Ph.D.
National Eye Institute
Telephone: 301-451-2020
Email: [email protected]